Lunit, a medical AI company, said Tuesday that it has signed an agreement for medical device distribution and supply with Dongkook Lifescience.
|Lunit CEO Suh Beom-seok (right) and Dongkook Lifescience CEO Jung Ki-ho hold up their agreement at Lunit’s headquarters in Gangnam-gu, Seoul, Tuesday.|
Under the accord, Dongkook will take charge of marketing, product promotion and other publicity activities for product sales, and service infrastructure for Lunit Insight, an artificial intelligence (AI)-based image detection assistance software.
Lunit Insight inputs and analyzes the chest X-ray (CXR) images of a patient and displays the degree of the suspected pulmonary nodule with an accuracy of 97 to 99 percent, which in turn helps doctors diagnose pulmonary nodule.
In August, the Ministry of Food and Drug Safety (MFDS) approved the platform as Korea’s second artificial intelligence (AI)-based medical device.
“The company expects that through this agreement, ‘Lunit Insight,’ which can improve the accuracy of diagnosis and treatment efficiency of chest X-ray images, will be commercialized so that early detection of lung cancer and prompt treatment of patients will become possible,” Lunit CEO Suh Beom-seok said.
Dongkook Lifescience CEO Jung Ki-ho, also said, “Through the technology radiologists will be able to help diagnose lung cancer more quickly and easily.”
<© Korea Biomedical Review, All rights reserved.>